Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance Biotherapeutics (NASDAQ: IOVA) recently reported strong Q2 earnings, with revenue increasing by 66% due to high demand for its cancer treatment, Amtagvi. The company also significantly reduced its net losses, leading to a surge in stock value and a new 52-week high. Despite past struggles, the approval of Amtagvi makes Iovance a more attractive, albeit still risky, investment with potential for further growth and profitability.